FEATURED NEWS

    MORE NEWS...

  • New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury

    SANTA BARBARA, Calif., October 20, 2014 — VG Life Sciences Inc., (OTCQB: VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin […]


    READ MORE »
  • VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace

    SANTA BARBARA, Calif., October 16, 2014 — VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. Company Achieves Key Milestone with Upgrade to OTCQB Marketplace VG Life Sciences is pleased to announce it has been approved to upgrade from the OTC Pink […]


    READ MORE »
  • VG Life Sciences, Inc. Announces SEC Form 10 Review Complete

    SANTA BARBARA, Calif., October 14, 2014 (GLOBE NEWSWIRE) — VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company’s Form 10 filing. The […]


    READ MORE »